#United States #San Francisco #AI-Powered #Eko Health #SENSORA

Major Advancement in Heart Disease Detection with Eko Health

In a significant move towards improving early heart disease diagnosis, Eko Health, a frontrunner in AI-driven cardiac and pulmonary care, has recently secured critical recognition from the Centers for Medicare & Medicaid Services (CMS). This breakthrough is part of the July 2025 update to the Hospital Outpatient Prospective Payment System (OPPS). The update incorporates Eko's SENSORA platform, introducing a new Category III CPT code with a reimbursement rate of $128.90 per use.

This pivotal acknowledgment not only highlights federal support for AI-enabled cardiac disease detection but also lays the groundwork for broader adoption among healthcare providers. The reimbursement framework established by this ruling enables hospitals and health systems to incorporate SENSORA into their routine outpatient cardiac evaluations, creating a clear financial pathway for using advanced technology in these settings.

The SENSORA platform, designed to enhance routine examinations, addresses critical gaps in heart disease detection. Heart disease continues to be the leading cause of death in the United States, accounting for nearly one in five fatalities, according to CDC statistics. Unfortunately, many serious heart conditions—such as low ejection fraction, atrial fibrillation, and valvular heart disease—often go unnoticed during standard exams, especially in time-constrained care environments. SENSORA aims to close this diagnostic gap by leveraging real-time AI analysis and delivering rapid insights in less than a minute, effectively enhancing the identification of structural murmurs and low ejection fractions.

Connor Landgraf, co-founder and CEO of Eko Health, emphasized the importance of this new CPT code in supporting healthcare providers. "As we confront our heart disease epidemic, empowering front-line providers with cutting-edge tools like SENSORA is essential to identify cardiovascular disease at earlier stages," he noted.

The recognition of SENSORA is complemented by the newly issued Category III CPT code from the American Medical Association (AMA), coming into effect on July 1, 2025. This milestone underscores the growing institutional recognition of the clinical utility of algorithmic cardiac support tools in enhancing patient care across diverse settings.

Dr. Steven Steinhubl, chair of Eko's Clinical Advisory Board, shared his perspective on this advancement, stating, "This isn't just a futuristic promise—it's a tool available today to improve the accuracy and access of heart disease identification." The ability of SENSORA to provide clinicians with real-time insights represents a crucial development in tackling the problem of undertreated heart disease.

Clinical evidence supporting SENSORA's effectiveness has been established through peer-reviewed publications in esteemed journals. A multicenter study published in The Lancet Digital Health validated SENSORA's low ejection fraction algorithm, revealing 85% sensitivity and 70% specificity from a single point of auscultation, thereby facilitating earlier identification of heart failure. Another study featured in Circulation demonstrated that the SENSORA platform significantly increased the sensitivity for detecting structural murmurs compared to traditional auscultation methods (90% sensitivity vs. 43% sensitivity), enhancing the effective identification of valvular heart disease.

These findings garnish urgency to deploy FDA-cleared, AI-powered detection technologies such as SENSORA in everyday medical practices, particularly where early intervention can significantly alter outcomes for patients.

How SENSORA Functions

Eko Health's SENSORA platform, which has been approved by the FDA and clinically validated, integrates seamlessly with Eko's digital stethoscopes to provide assistive, real-time insights during routine examinations. Designed for effortless incorporation into clinical workflows, SENSORA serves as a scalable solution for improving early detection and bridging gaps in access to specialized cardiac evaluation. With a newly issued CPT code poised for implementation in July 2025, Eko Health is set to collaborate with public health agencies, health systems, and commercial payers to facilitate reimbursement and encourage widespread clinical adoption of this forward-looking technology.

About Eko Health

Headquartered in Emeryville, California, Eko Health is renowned for its pioneering efforts in early disease detection, focusing on heart and lung conditions through a suite of digital stethoscopes, ECG devices, and state-of-the-art software incorporating AI analysis. With over 650,000 devices sold globally, Eko Health remains dedicated to advancing the standards of patient care, ensuring that healthcare professionals have the tools to diagnose, manage treatment, and enhance patient outcomes effectively. For additional resources and information about SENSORA, visit ekohealth.com/reimbursement. Eko Health continues to strive towards improving overall healthcare with advanced technology and innovative solutions.